🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesSUSTAIN-6 to SELECT — my results so far Page 3

SUSTAIN-6 to SELECT — my results so far

CanadaChris Tue, Jan 27, 2026 at 10:11 AM 13 replies 1,000 viewsPage 3 of 3
BethLabQueen
Senior Member
1,234
5,678
May 2024
Virginia
Online
Jan 31, 2026 at 9:37 AM#11
KevinCompounds said:
The dose-response is real but shallow at the top.

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

Last edited: Jan 31, 2026 at 10:37 AM
45 18maya_sedona, stefan_berlin, Dr.EM_Chicago and 42 others
Reply Quote Save Share Report
mark_tokyo
Member
456
1,890
Jun 2024
Tokyo, JP
Feb 1, 2026 at 3:38 AM#12
JakeBK_lifts said:
Agreed, though "tolerable" needs defining.

This answered a question I did not know how to ask. Adding it to my notes with a link back to this thread.

Last edited: Feb 1, 2026 at 6:38 AM
46 19bri_stats, pete_manc_UK, anna.melb_AU and 43 others
Reply Quote Save Share Report
anna.melb_AU
Member
678
2,890
Apr 2024
Melbourne, AU
Feb 1, 2026 at 9:39 PM#13
KevinCompounds said:
The dose-response is real but shallow at the top.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

47 20emma_london, tammy_FL, Dr.LipidDallas and 44 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
labquiet_amy
Senior Member
1,234
6,789
Mar 2024
Cambridge, MA
Feb 2, 2026 at 3:40 PM#14
CanadaChris said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

CRP reduction on cardiovascular risk — this is the lab result that excites me most:

Baseline hsCRP: 10.0 mg/L (high cardiovascular risk)
Month 6 hsCRP: 2.5 mg/L (moderate risk)
Month 12 hsCRP: 0.7 mg/L (low risk)

This level of inflammatory marker reduction is comparable to what you'd see with statin therapy. Combined with the weight loss, my 10-year ASCVD risk score dropped from 17% to 5%. My cardiologist is genuinely impressed.

48 21bri_stats, pete_manc_UK, anna.melb_AU and 45 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Feb 3, 2026 at 9:42 AM#15

Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. Tagging this one for the weekly digest.

49 22PurityPaulOR, MaxMetOK, MounjBrad and 46 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register